Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Stock Purchase Agreements (Narrative) (Details)

Collaboration and Stock Purchase Agreements (Narrative) (Details) $ / shares in Units, $ in Thousands									1 Months Ended		3 Months Ended		6 Months Ended
	Jul. 28, 2023 USD ($)	Apr. 24, 2023 USD ($)	Feb. 03, 2023 USD ($)	Jan. 27, 2023 shares	Dec. 30, 2022 USD ($) shares	Oct. 11, 2022 USD ($)	Feb. 24, 2021 USD ($) Milestone	Nov. 12, 2018	Feb. 28, 2023 USD ($) $ / shares shares	Feb. 28, 2019 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Collaboration revenue											$ 183	$ 577	$ 364	$ 1,154
Sale of stock, number of shares issued \| shares					4,900,000				1,180,000
Stock offering, price per share \| $ / shares									$ 5.25
Sale of Stock, Consideration Received on Transaction					$ 150,000				$ 6,700
UBriGene
Bookvalue of lease liability											3,800		3,800
UBriGene \| Subsequent events
Consideration Transferred	$ 6,000
Contingent liability	$ 5,000
Contingent consideration period	2 years
Contingent liability, Issuance of equity securities	$ 10,000
Contingent consideration, Proposed lease period	2 years
Bookvalue of lease liability	$ 3,800
Cyprium \| Sentnyl
Upfront fees payment							$ 8,000
Payments of milestones							$ 12,000
Number of development milestones \| Milestone							2
Collaboration revenue											$ 200	$ 600	$ 400	$ 1,200
Avenue
Sale of stock, number of shares issued \| shares				448,000
Avenue \| InvaGen
Payments of milestones			$ 200
Percentage of shares repurchased						100.00%
Purchase price of shares repurchased						$ 3,000
Percentage of contingent fee payable						7.50%
Contingent fee payable from proceeds of future financing						$ 4,000
Aevitas \| Maximum \| Asset purchase agreement to acquire Aevitas proprietary rights
Upfront payment to be paid		$ 140,000
SPMA \| Avenue \| InvaGen
Sale of stock, ownership percentage after the transaction								33.30%
FDA approval of the NDA \| Cyprium \| Sentnyl \| Maximum
Payments of milestones							$ 255,000
Strategic Transaction, First Stage \| SPMA \| Avenue \| InvaGen
Sale of stock, ownership percentage after the transaction										33.30%
Sale of stock, number of shares issued \| shares										400,000
Stock offering, price per share \| $ / shares										$ 90.00
Sale of Stock, Consideration Received on Transaction										$ 35,000